(S)-tert-butyl 2-(3,5-difluorophenoxymethyl)pyrrolidine-1-carboxylate | 174213-33-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: (S)-tert-butyl 2-(3,5-difluorophenoxymethyl)pyrrolidine-1-carboxylate
• 英文别名: (S)-N-BOC-2-(3.5-difluorophenoxymethyl)-pyrrolidine；(S)-N-BOC-2-(3,5-difluorophenoxymethyl)pyrrolidine；tert-butyl (2S)-2-[(3,5-difluorophenoxy)methyl]pyrrolidine-1-carboxylate
• CAS: 174213-33-3
• 化学式: C₁₆H₂₁F₂NO₃
• 分子量: 313.344
• InChiKey: XMYCOCBEFALDBO-ZDUSSCGKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  22
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  38.8
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (S)-tert-butyl 2-(3,5-difluorophenoxymethyl)pyrrolidine-1-carboxylate 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 生成 2(S)-(3,5-difluorophenoxymethyl)pyrrolidine
  参考文献：
  名称：

  2-(Aryloxymethyl) azacyclic analogues as novel nicotinic acetylcholine receptor (nAChR) ligands

  摘要：

  A series of 2-(aryloxymethyl) azetidine and pyrrolidine nAChR ligands in which the 3-pyridyl moiety of a previously described series(1) was replaced by a substituted phenyl group was explored. Aromatic substitution afforded analogues with K-i values ranging from 3 Co >10,000 nM. Generally, substitution at the ortho- and para-position was unfavorable, whereas electron-withdrawing groups at the meta-position improved the Ki values. Copyright (C) 1996 Elsevier Science Ltd

  DOI：

  10.1016/0960-894x(96)00416-7
• 作为产物：
  描述：

  BOC-L-脯氨酸 在 硼烷 作用下， 生成 (S)-tert-butyl 2-(3,5-difluorophenoxymethyl)pyrrolidine-1-carboxylate
  参考文献：
  名称：

  2-(Aryloxymethyl) azacyclic analogues as novel nicotinic acetylcholine receptor (nAChR) ligands

  摘要：

  A series of 2-(aryloxymethyl) azetidine and pyrrolidine nAChR ligands in which the 3-pyridyl moiety of a previously described series(1) was replaced by a substituted phenyl group was explored. Aromatic substitution afforded analogues with K-i values ranging from 3 Co >10,000 nM. Generally, substitution at the ortho- and para-position was unfavorable, whereas electron-withdrawing groups at the meta-position improved the Ki values. Copyright (C) 1996 Elsevier Science Ltd

  DOI：

  10.1016/0960-894x(96)00416-7

文献信息

• ISATIN DERIVATIVES FOR USE AS IN VIVO IMAGING AGENTS
  申请人：Aboabye Eric Ofori

  公开号：US20110195024A1

  公开（公告）日：2011-08-11

  Isatin 5-sulfonamide derivatives, pharmaceutical compositions comprising the derivatives, their use as molecular imaging agents, their use for the diagnosis or treatment of diseases or disorders associated with dysregulation of apoptosis, methods for synthesizing the derivatives, methods for the molecular imaging of caspase activity and apoptosis, and methods of assessing the therapeutic effect of a test substance on caspase activity are disclosed.

  异吲哚啉-5-磺酰胺衍生物，包括这些衍生物的药物组合物，它们作为分子成像剂的用途，它们用于与凋亡失调相关的疾病或紊乱的诊断或治疗，合成这些衍生物的方法，用于测定caspase活性和凋亡的分子成像方法，以及评估试验物质对caspase活性的治疗效果的方法。
• 2-((nitro)phenoxymethyl) heterocyclic compounds that enhance cognitive
  申请人：Abbott Laboratories

  公开号：US05472958A1

  公开（公告）日：1995-12-05

  Selective and potent cholinergic ligands selective for neuronal nicotinic cholinergic channel receptors, which ligands have the formula: ##STR1## as well as pharmaceutically-acceptable salts or prodrugs thereof, which are useful in the treatment of dementias, attentional hyperactivity disorder, or substance abuse withdrawal characterized by decreased cholinergic function, one of which is also an analgesic agent, and one of which is an agent useful for treating anxiety associated with cognitive impairment.

  具有以下公式的选择性和有效的胆碱能配体，选择性作用于神经元烟碱性胆碱通道受体，以及其药学上可接受的盐或前药，用于治疗因胆碱能功能降低而表现出的痴呆症、注意力过度活动障碍或物质滥用戒断症状，其中一个还是镇痛剂，另一个是用于治疗与认知障碍相关的焦虑症的药物。
• US5472958A
  申请人：——

  公开号：US5472958A

  公开（公告）日：1995-12-05
• US8961930B2
  申请人：——

  公开号：US8961930B2

  公开（公告）日：2015-02-24
• [EN] ISATIN DERIVATIVES FOR USE AS IN VIVO IMAGING AGENTS<br/>[FR] DÉRIVÉS D'ISATINE POUR UTILISATION EN TANT QU'AGENTS D'IMAGERIE IN VIVO
  申请人：IMP INNOVATIONS LTD

  公开号：WO2010026388A1

  公开（公告）日：2010-03-11

  The present invention provides isatin 5-sulfonamide derivatives, pharmaceutical compositions comprising said derivatives, their use as molecular imaging agents, their use for the diagnosis or treatment of diseases or disorders associated with dysregulation of apoptosis, methods for synthesizing said derivatives, methods for the molecular imaging of caspase activity and apoptosis, and methods of assessing the therapeutic effect of a test substance on caspase activity.